Sixty adolescents and young adults with ESKD ( 25 on hemodialysis and 35 kidney transplant recipients ) were randomized 1:1 to receive a traditional trivalent split virion vaccine ( TIIV ) or a virosome-adjuvanted trivalent inactivated influenza vaccine ( VATIIV ) .